Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.

Montreal’s First Shroom Dispensary Is Set to Open in Less Than Three Weeks | Psychedelic Spotlight

While news about the potential benefits of psilocybin are slowly but surely beginning to populate social media platforms, psychedelic dispensaries have started to pop left and right

June 15, 2023

Late-stage results set up Cytokinetics heart drug to compete with Bristol

Late-stage results of Cytokinetics’ drug for a rare heart disease suggest it can compete with a similar treatment sold by Bristol Myers Squibb on efficacy

May 13, 2024

Camena Bioscience appoints Dr. Nicola Thompson as Chair of the Board

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.